Dr. Wang has made distinguished contributions to the field of genetics of cardiovascular and neurological diseases by identifying eight genes for single gene disorders and three candidate genes for common complex disease, and by identifying novel molecular mechanisms underlying channelopathies and other diseases. He was noted for reporting the discoveries of the first Brugada syndrome gene (SCN5A), the most common gene for long QT syndrome (LQTS) (KCNQ1), one of the first two genes reported for LQTS in the same issue of Cell (SCN5A), LQTS gene KCNE1, the first gene for autosomal recessive atrial fibrillation (NUP155), atrial fibrillation gene SCN3B, the first gene for vascular disease Klippel-Trenaunay syndrome (AGGF1), and the first gene for co-existent paroxysmal dyskinesia and generalized epilepsy (KCNMA1).
Dr. Wang also identified candidate genes for familial, early-onset coronary artery disease (CAD), completed the first genome-wide association study for CAD in a non-Caucasian population and identified C6orf105 as a new CAD susceptibility gene. Dr. Wang’s early discoveries on cardiac arrhythmias genes have been translated into the first commercial genetic testing kit in the field of cardiovascular medicine (Familion Test), which realized the first successful case of personalized genomic medicine in cardiovascular medicine and saved many human lives. Dr. Wang has identified a protein MOG1 that interacts with the cardiac sodium channel and regulates trafficking of this channel to cell membranes, and established AGGF1 as a VEGF-A-like angiogenic factor for specifying veins (in contrast to arterial specification by VEGF-A).